China's Organ Donation System Overhauled
This article was originally published in PharmAsia News
China's organ donation and transplant program will provide a platform for facilitating technology transfer and enhancing the establishment of the China Organ Donor System. The collaborative project between the Ministry of Health and Novartis was launched in 2003 to promote organ donation and transplant development in China (PharmAsia News, July 21, 2008). Last month, the program actively supported the Organ Transplantation Committee's meeting on organ donation mobilization, CODS establishment and trial initiation. A recent organ donation and transplant seminar discussed supplementary clauses for regulations on human organ transplantation; the program will strengthen live organ transplant standardization and set up an organ transplant data center. (Click here for more - Chinese Language)
You may also be interested in...
China's Ministry of Health's International Health Exchange and Cooperation Center and Novartis Foundation for People and the Environment have kicked off the second phase of China's first and largest collaborative international project on organ donation and transplant. The project, with a total funding of up to 20 billion yuan ($2.92 billion) will concentrate on organ transplant academic exchange, public education and publicity, a study on brain death, as well as R&D on living related transplantation. The Novartis foundation will invest 2 million Swiss francs in phase two of the project from 2008 to 2012. MOH will accelerate China's establishment of an organ transplant management system and seek out more international organizations and relevant parties to develop the program. (Click here for more - Chinese Language)
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.